Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Endosialin (CD248) Cancer Role and Therapeutics: 33 Years on.

Molecular cancer therapeutics·2026
Same author

Lamin A/C loss promotes R-loop-mediated genomic instability and poor survival in small-cell lung cancer.

Proceedings of the National Academy of Sciences of the United States of America·2025
Same author

High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids.

SLAS discovery : advancing life sciences R & D·2025
Same author

Lamin A/C Deficiency Drives Genomic Instability and Poor Survival in Small-Cell Lung Cancer through Increased R-loop Accumulation.

bioRxiv : the preprint server for biology·2025
Same author

RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.

Cancer research communications·2025

Related Experiment Video

Updated: May 7, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Targets in small cell lung cancer.

Beverly A Teicher1

  • 1National Cancer Institute, Bethesda, MD, United States.

Biochemical Pharmacology
|October 5, 2013
PubMed
Summary

Recurrent small cell lung cancer (SCLC) is challenging, but genomic studies reveal numerous genetic abnormalities. Identifying overexpressed targets like NCAM/CD56 offers potential therapeutic avenues despite challenges with normal tissue expression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Recurrent small cell lung cancer (SCLC) presents significant therapeutic challenges.
  • Genomic technologies are increasingly used to understand the molecular landscape of SCLC.
  • Several cell surface receptors and developmental transcription factors are aberrantly expressed in SCLC.

Purpose of the Study:

  • To elucidate the genetic abnormalities in recurrent small cell lung cancer.
  • To identify potential therapeutic targets overexpressed in SCLC.
  • To review the current understanding of molecular alterations in SCLC.

Main Methods:

  • Genomic profiling of SCLC specimens.
  • Analysis of cell surface receptor and transcription factor expression.
Keywords:
CD24CD56MycSCLCSmall cell lung cancer

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Related Experiment Videos

Last Updated: May 7, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

  • Review of existing literature on SCLC molecular abnormalities.

    • Main Results:

    • Overexpression of GPCRs (bradykinin, chemokine CXCR4, vasopressin, bombesin receptors), GLUT1, PETA/CD151, ALCAM/CD166, and NCAM/CD56 in SCLC.
    • IGF1R and FGFRs are frequently overexpressed, though SCLC is not typically considered RTK-driven.
    • Aberrant expression of developmental transcription factors (ASCL1, SOX2, OCT4, NANOG) and potential MYC-driven alterations identified.

    Conclusions:

    • NCAM/CD56 is overexpressed in most SCLC cases and is a target for antibody drug conjugates.
    • A significant challenge for targeted therapy is the expression of potential targets in normal tissues.
    • Continued research into SCLC molecular abnormalities is crucial for developing effective therapeutics.